PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.
Vidarsdottir L, Azimi A, Das I, Sigvaldadottir I, Suryo Rahmanto A, Petri A, Kauppinen S, Ingvar C, Jönsson G, Olsson H, Frostvik Stolt M, Tuominen R, Sangfelt O, Pokrovskaja Tamm K, Hansson J, Grandér D, Egyházi Brage S, Johnsson P.
Vidarsdottir L, et al. Among authors: das i.
Sci Rep. 2021 May 26;11(1):11023. doi: 10.1038/s41598-021-89389-9.
Sci Rep. 2021.
PMID: 34040017
Free PMC article.